EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Anti-Sez6L2 antibody–associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy

Ya Gao, Ruisheng Duan

Neurological Sciences · 2026-05 · 47 (5)

DOI: 10.1007/s10072-026-09017-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neurological Sciences, online erschienen am 18.04.2026. Verfasst von Ya Gao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology I, Hebei Provincial People's Hospital, No. 348, Heping West Road, Shijiazhuang, 050000, Hebei Province, China. Hauptthemen laut MEDLINE: Autoantibodies, Cerebellar Ataxia, Rituximab, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-Sez6L2 (seizure-related 6 homolog-like 2) antibody–associated autoimmune cerebellar ataxia is an exceptionally rare neuroimmunological disorder, with only a limited number of cases reported to date. Its clinical spectrum and optimal therapeutic strategies remain incompletely characterized. Case presentation We report a 77-year-old woman who developed a subacute-to-chronic progressive cerebellar ataxia accompanied by oculomotor abnormalities, a forward-leaning posture, and gait initiation failure.. Neuroimaging studies revealed no structural or neoplastic lesions sufficient to account for the neurological deterioration. Cell-based assays detected anti-Sez6L2 IgG antibodies in both serum and cerebrospinal fluid. The patient exhibited only limited and unsustained improvement following first-line immunotherapies, including corticosteroids and intravenous immunoglobulin. After confirmation of an antibody-mediated mechanism, treatment was escalated to B-cell–depleting therapy with rituximab, resulting in clinical improvement accompanied by a reduction in cerebrospinal fluid antibody titers.

Conclusion

This case represents a rare presentation of anti-Sez6L2 antibody–associated autoimmune cerebellar ataxia and provides additional clinical and immunological evidence supporting the relevance of this antibody. Furthermore, it suggests that rituximab may represent a potentially valuable therapeutic option in patients with insufficient responses to first-line immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesCerebellar AtaxiaRituximabAutoimmune Diseases of the Nervous SystemHumansFemaleAgedNeuroimagingImmunotherapy

Stichwörter der Autor:innen

Autoimmune cerebellar ataxiaNeuroimmunologyRare antibodyRituximabSez6L2

Substanzen

anti-sez6l2 autoantibodyAutoantibodiesRituximab

Autor:innen und Institutionen

  • Department of Neurology I, Hebei Provincial People's Hospital, No. 348, Heping West Road, Shijiazhuang, 050000, Hebei Province, China.
  • Key Laboratory of Brain Network and Cognitive Impairment Disorders of Hebei Province, 1801 Building E, Zhongchu Plaza, 050000, Shijiazhuang, China.
  • Department of Neurology I, Hebei Provincial People's Hospital, No. 348, Heping West Road, Shijiazhuang, 050000, Hebei Province, China. 13832140261@126.com.
  • Key Laboratory of Brain Network and Cognitive Impairment Disorders of Hebei Province, 1801 Building E, Zhongchu Plaza, 050000, Shijiazhuang, China. 13832140261@126.com.

Zitieren

APA

Gao, Y., & Duan, R. (2026). Anti-Sez6L2 antibody–associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy. Neurological Sciences, 47(5). https://doi.org/10.1007/s10072-026-09017-0

Vancouver

Gao Y, Duan R. Anti-Sez6L2 antibody–associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy. Neurological Sciences. 2026;47(5). doi:10.1007/s10072-026-09017-0

BibTeX
@article{Gao2026,
  author = {Gao, Ya and Duan, Ruisheng},
  title = {Anti-Sez6L2 antibody–associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy},
  journal = {Neurological Sciences},
  year = {2026},
  volume = {47},
  number = {5},
  doi = {10.1007/s10072-026-09017-0}
}
Kostenlos starten →